Kbc Group Nv Bluebird Bio, Inc. Transaction History

Kbc Group Nv

$31.5 Billion
Q1 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$8.96 - $16.31 $27,193 - $49,500	-3,035 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$11.24 - $21.0 $2.51 Million - $4.7 Million	-223,730 Reduced 98.66%	3,035 $58,000
Q2 2021 Aug 11, 2021	BUY	$18.04 - $22.09 $1.53 Million - $1.87 Million	84,681 Added 59.6%	226,765 $7.25 Million
Q1 2021 Apr 26, 2021	BUY	$16.59 - $33.89 $771,285 - $1.58 Million	46,491 Added 48.63%	142,084 $4.28 Million
Q4 2020 Feb 10, 2021	BUY	$27.5 - $37.92 $626,725 - $864,196	22,790 Added 31.3%	95,593 $4.14 Million

Q3 2020 Oct 28, 2020	BUY	$34.44 - $43.75 $1.16 Million - $1.48 Million	33,767 Added 86.5%	72,803 $3.93 Million
Q2 2020 Aug 10, 2020	BUY	$27.12 - $45.97 $160,469 - $272,004	5,917 Added 17.87%	39,036 $2.38 Million
Q1 2020 May 04, 2020	BUY	$26.16 - $63.5 $11,301 - $27,432	432 Added 1.32%	33,119 $1.52 Million
Q4 2019 Feb 11, 2020	BUY	$46.96 - $61.67 $418,319 - $549,356	8,908 Added 37.46%	32,687 $2.87 Million
Q3 2019 Nov 07, 2019	BUY	$59.47 - $93.1 $1.41 Million - $2.21 Million	23,689 Added 26321.11%	23,779 $1.41 Million
Q2 2019 Dec 03, 2019	SELL	$75.84 - $105.21 $1.4 Million - $1.95 Million	-18,491 Reduced 99.52%	90 $11,000
Q2 2019 Jul 30, 2019	BUY	$75.84 - $105.21 $1.4 Million - $1.95 Million	18,491 Added 20545.56%	18,581 $0
Q1 2019 Dec 03, 2019	SELL	$64.44 - $104.11 $1.12 Million - $1.81 Million	-17,371 Reduced 99.48%	90 $14,000
Q1 2019 May 10, 2019	BUY	$64.44 - $104.11 $1.12 Million - $1.81 Million	17,371 Added 19301.11%	17,461 $0
Q4 2018 Dec 03, 2019	SELL	$59.1 - $93.26 $1.07 Million - $1.69 Million	-18,145 Reduced 99.51%	90 $9,000
Q4 2018 Jan 31, 2019	BUY	$59.1 - $93.26 $1.07 Million - $1.69 Million	18,145 Added 20161.11%	18,235 $1.17 Million
Q3 2018 Dec 03, 2019	SELL	$88.86 - $117.49 $1.34 Million - $1.77 Million	-15,034 Reduced 99.4%	90 $13,000
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $1.34 Million - $1.77 Million	15,034 Added 16704.44%	15,124 $0
Q2 2018 Dec 03, 2019	SELL	$99.64 - $127.59 $1.1 Million - $1.41 Million	-11,078 Reduced 99.19%	90 $14,000
Q2 2018 Aug 03, 2018	BUY	$99.64 - $127.59 $1.11 Million - $1.42 Million	11,123 Added 24717.78%	11,168 $0
Q1 2018 Dec 03, 2019	SELL	$105.8 - $150.94 $1.01 Million - $1.44 Million	-9,524 Reduced 99.53%	45 $8,000
Q1 2018 May 09, 2018	BUY	$105.8 - $150.94 $1.01 Million - $1.44 Million	9,524 Added 21164.44%	9,569 $0
Q4 2017 Dec 03, 2019	SELL	$81.25 - $130.7 $898,868 - $1.45 Million	-11,063 Reduced 99.59%	45 $8,000
Q4 2017 Feb 07, 2018	SELL	$81.25 - $130.7 $35,343 - $56,854	-435 Reduced 3.77%	11,108 $0
Q3 2017 Nov 13, 2017	BUY	$57.74 - $91.42 $666,492 - $1.06 Million	11,543	11,543 $0

Others Institutions Holding BLUE

# of Institutions

173

Shares Held

104M

Call Options Held

827K

Put Options Held

1.23M

Black Rock Inc. New York, NY

15.2M
Shares

$14.9 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.5M
Shares

$10.3 Million
0.0% of portfolio
Granahan Investment Management, LLC Waltham, MA

7.71M
Shares

$7.56 Million
0.35% of portfolio
Ameriprise Financial Inc Minneapolis, MN

6.39M
Shares

$6.26 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

6.24M
Shares

$6.11 Million
0.0% of portfolio

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $75.6M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account